Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemo With Either Vinorelbine or Pemetrexed for the Adj Tx of Early Stage NSCLC in Patients Using Genomic Expression Profiles of Chemo Sensitivity to Guide Therapy

Inclusion Criteria:

Patients are eligible to be included in the study only if they meet all of the following
criteria:

1. Patients with completely resected stage IB (> 4 cm), II, or IIIA Non-Squamous NSCLC.
Patient must be enrolled and begin therapy within 4 to 12 weeks from the date of
complete surgical resection.

2. Fresh tissue must be available for genomics expression profiling.

3. ECOG performance status of 0 or 1.

4. NO prior chemotherapy, radiation therapy, or biologic/targeted therapy within the
last 5 years. Prior therapy with low dose methotrexate or similar medications is
allowed if therapy used to treat non-malignant conditions.

5. Age ≥ 18 years.

6. No previous or concomitant malignancy in the past 5 years other than
curatively-treated carcinoma in situ of the cervix, or basal cell or squamous cell
carcinoma of the skin.

7. No other serious medical or psychiatric illness.

8. Signed informed consent.

9. Required laboratory data within one week of enrollment:

- ANC or AGC ≥ 1500 per uL;

- Platelets ≥ 100,000 per uL;

- Total bilirubin ≤ 1.5 mg/dL;

- Creatinine ≤ 2 mg/dL; creatinine clearance ≥ 45 mL/min;

- SGOT/SGPT ≤ 1.5x ULN.

10. Females of child-bearing potential (not surgically sterilized and between menarche
and 1 year post menopause) must test negative for pregnancy within 7 days prior to or
at the time of enrollment based on a serum pregnancy test. Both sexually active males
and females of reproductive potential must agree to use a reliable method of birth
control, as determined by the patient and their health care team, during the study
and for 3 months following the last dose of study drug.

Exclusion Criteria:

Patients will be excluded from the study if they meet any of the following criteria:

1. Treatment within the last 30 days with a drug that has not received regulatory
approval for any indication at the time of study entry.

2. Concurrent administration of any other anti-tumor therapy (see #4 inclusion for
exceptions).

3. Inability to comply with protocol or study procedures.

4. Active infection requiring IV antibiotics, antifungal or antiviral agents, that in
the opinion of the investigator would compromise the patient's ability to tolerate
therapy.

5. Major surgery (other than definitive lung cancer surgery) within two weeks of study
or other serious concomitant systemic disorders that, in the opinion of the
investigator, would compromise the safety of the patient or compromise the patient's
ability to complete the study.

6. Myocardial infarction having occurred less than 6 months before inclusion, any known
uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac
failure not controlled by medications.

7. Contraindication to corticosteroids.

8. Inability or unwillingness to take folic acid or vitamin B12 supplementation.

9. Unwillingness to stop taking herbal supplements while on study.

10. Presence of clinically significant third-space fluid collections (for example,
ascites or pleural effusions) that cannot be controlled by drainage or other
procedures prior to study entry and throughout study enrollment as the distribution
of pemetrexed in this fluid space is not fully understood.

11. Inability to discontinue administration of aspirin at a dose > 1300 mg/day or other
long acting, non-steroidal anti-inflammatory agents for 2 days before, the day of,
and 2 days after the dose of pemetrexed (5 days prior for long-acting agents such as
piroxicam). Moderate dose ibuprofen may be continued.

12. Female patients that are pregnant or breast-feeding.